^
BIOMARKER:

MET amplification + EGFR mutation

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase, EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
MET amplification + EGFR mutation
Non Small Cell Lung Cancer
osimertinib + tepotinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET amplification + EGFR mutation
Non Small Cell Lung Cancer
lazertinib + ABN401
Sensitive
:
D
ESMO 2022 - 3 weeks - (New D)
MET amplification + EGFR mutation
Non Small Cell Lung Cancer
gefitinib + tepotinib
Sensitive
:
C3
MET amplification + EGFR mutation
Non Small Cell Lung Cancer
crizotinib
Sensitive
:
C3
MET amplification + EGFR mutation
Non Small Cell Lung Cancer
gefitinib + capmatinib
Sensitive
:
C3
MET amplification + EGFR mutation
Non Small Cell Lung Cancer
osimertinib + savolitinib
Sensitive
:
C3
MET amplification + EGFR mutation
Non Small Cell Lung Cancer
osimertinib
Resistant
:
D